

21 December 2023

Pre-quotation disclosure

The following information is provided by Arcadium Lithium plc (ASX: LTM) (**Arcadium**) to the Australian Securities Exchange (**ASX**) for release to the market in connection with the admission of Arcadium to the official list of ASX as a foreign exempt listing and the official quotation of Arcadium's CHESS Depositary Interests (**CDIs**) on ASX.

Capitalised terms which are otherwise not defined in this document have the same meaning they have in the Scheme Booklet released by Allkem Limited (ASX: AKE) (**Allkem**) to ASX on 9 November 2023 (**Scheme Booklet**).

1 **Scheme is Effective**

As announced by Allkem, the Scheme became effective on 21 December 2023.

2 **Conditions precedent to Scheme**

All conditions precedent to the implementation of the Scheme have been satisfied or waived.

3 **Deed Poll**

The Deed Poll remains in full force and effect.

4 **Despatch dates**

In relation to the Arcadium CDIs issued under the Scheme and which are held on the CHESS sub-register, a CHESS allotment confirmation notice from Arcadium under ASX Settlement Operating Rule 8.9.1 will be despatched to the relevant Arcadium CDI holders on 5 January 2024.

In relation to all other Arcadium CDIs issued under the Scheme, issuer sponsored holding statements will be despatched to the relevant Arcadium CDI holders on 5 January 2024.

Arcadium CDIs are expected to commence trading on ASX, initially on a deferred settlement basis and then, with effect from 5 January 2024, on a normal (T+2) settlement basis.

Arcadium Shares are expected to commence trading on the New York Stock Exchange (**NYSE**) on 4 January 2024 (New York time).

It is the responsibility of each Allkem Shareholder who will receive Arcadium CDIs under the Scheme to confirm their holdings of Arcadium CDIs before they trade them, to avoid the risk of committing to sell more than will be issued to them. Allkem Shareholders who sell Arcadium CDIs before they receive their holding statements or confirm their holdings of Arcadium CDIs do so at their own risk. Neither Allkem nor Arcadium takes any responsibility for such trading. Further details in relation to deferred settlement trading of Arcadium CDIs is set out in section 3.2(e) of the Scheme Booklet.

Allkem Shareholders should be aware that Arcadium Shares will not trade on a deferred settlement basis on the NYSE. Accordingly, Allkem Shareholders who will receive Arcadium Shares under the Scheme (being eligible Allkem Canadian branch register shareholders who do not validly elect to receive Arcadium CDIs, and eligible Allkem principal register shareholders who validly elect to receive Arcadium Shares) will not be able to trade their Arcadium Shares until after commencement of trading of Arcadium Shares on the NYSE (which is expected to commence at 9:30am (New York time) on 4 January 2024).

6 Basis of allocation of Arcadium CDIs and Arcadium Shares to Allkem Shareholders

The Scheme Booklet sets out the entitlements of Allkem Shareholders to receive Arcadium CDIs and Arcadium Shares. For further information, contact the Scheme Information Line on 1300 367 804 (within Australia) or +61 2 9066 6163 (outside Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday, excluding public holidays.

7 ASX Listing Rule waivers

7.1 ASX Listing Rule 1.13

ASX has granted Arcadium a waiver from ASX Listing Rule 1.13 to the extent necessary that, at the time of listing, Arcadium will not satisfy the assets test, but upon implementation of the acquisition of all of the shares in Allkem in return for the issue of Arcadium Shares or CDIs by way of the Scheme and through Lightning-A Merger Sub, Inc. (which will be an indirect, wholly-owned subsidiary of Arcadium) merging with Livent Corporation (**Livent**) (with Livent surviving the merger) in return for the issue of Arcadium Shares to Livent stockholders by way of the US Merger, it will meet the assets test set out in ASX Listing Rule 1.13.

At all times prior to implementation of the Scheme and the US Merger, both Allkem and Livent separately satisfy the assets test set out in that rule. The waiver is required due to ASX timetable requirements which result in Arcadium being admitted to the ASX before completion of the US Merger.

7.2 ASX Listing Rule 2.7

ASX has granted Arcadium a waiver from ASX Listing Rule 2.7 to the extent necessary to permit Arcadium not to apply for quotation of ordinary fully paid shares to be settled in the form of CDIs which are issued as a result of holders of Arcadium Shares converting their shares to CDIs on or before the CDI issue date on the following conditions:

1. an application for quotation of newly issued CDIs issued into the Australian market is made on a monthly basis; and
2. an update of net changes in the number of CDIs that are quoted on ASX is provided to the market on a monthly basis and Arcadium completes and provides an Appendix 4A to ASX within five business days of the end of each month.